The Future of Cancer Immunotherapy
Related Experiment Video
Updated: Aug 8, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
1Clinical Research Unit, Oncology Dpt, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Abstract:
This article describes three emerging, novel cancer immunotherapies: BITE, TIL and cancer vaccines are therapies that recognize specific targets on cancer cells and trigger a specific immune response. So far, not all tumor types can benefit from these approaches the best results have been observed in hematological malignancies, melanoma, and lung cancer. These novel biological products are currently being tested in several cancer centers in Switzerland, and physicians must be familiar with these procedures, as some of their patients might be treated with such therapies in the near future.
Insights
Three novel cancer immunotherapies, including bispecific antibody (BITE) therapies, tumor-infiltrating lymphocyte (TIL) therapies, and cancer vaccines, show promise. These treatments target cancer cells to stimulate immune responses, with best results seen in specific cancers.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Emerging cancer immunotherapies are revolutionizing treatment paradigms.
- Bispecific antibody (BITE) therapies, tumor-infiltrating lymphocyte (TIL) therapies, and cancer vaccines represent novel approaches.
- Understanding these therapies is crucial for oncologists and researchers.
Purpose of the Study:
- To describe three novel cancer immunotherapies: BITE, TIL, and cancer vaccines.
- To highlight their mechanisms of action in triggering specific immune responses against cancer cells.
- To inform healthcare professionals about their current development and potential applications.
Main Methods:
- Review of emerging immunotherapeutic strategies.
- Description of the mechanisms of BITE, TIL, and cancer vaccine therapies.
- Analysis of current clinical testing and observed efficacy in different cancer types.
Main Results:
- BITE, TIL, and cancer vaccines are novel immunotherapies targeting specific cancer antigens.
- These therapies activate a targeted immune response against tumor cells.
- Optimal outcomes have been observed in hematological malignancies, melanoma, and lung cancer.
Conclusions:
- These novel immunotherapies offer new avenues for cancer treatment.
- Clinical trials are ongoing in Switzerland, indicating active research and development.
- Physicians should be prepared for the integration of these advanced therapies into patient care.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers